Merck & Co (MSD), Alexion, and AstraZeneca Rare Disease have reported positive topline outcomes from the Phase III KOMET ...

Rahway, New Jersey Wednesday, November 13, 2024, 13:00 Hrs [IST] ...

Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the ...

Adding a PD-1 inhibitor to standard of care improved disease-free survival (DFS) in stage III soft-tissue sarcoma of the ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous ...

KOMET phase III trial of Koselugo shows statistically significant and clinically meaningful ORR vs. placebo in adults with neurofibromatosis type 1: Cambridge, UK Wednesday, Novem ...

In 2024, we established a license and research collaboration with MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA) to identify novel targets for inflammatory diseases. In 2021, we entered into ...

The trial was funded by by a SU2C Catalyst® grant and was supported by Merck’s (known as MSD outside the United States and ...

Since 2017, Merck (known as MSD outside of the U.S. and Canada), GSK and Eisai have been partnering to donate Mectizan, albendazole, and DEC, respectively, to accelerate the elimination of LF in ...

MSD – known as Merck & Co in the US and Canada – said this morning that the phase 3 INTerpath-002 study will look at the combination as adjuvant therapy for patients with stage II, IIIA ...

In 2024, we established a license and research collaboration with MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA) to identify novel targets for inflammatory diseases. In 2021, we entered into ...